Lanoracopan clinical trials
Also written MY008211A.
How each study uses lanoracopan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lanoracopan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Wuhan Createrna Science and Technology Co., Ltd (11)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test lanoracopan, phase 3 first.
- Dec 2026Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal HemoglobinuriaPhase 2/3 · Wuhan Createrna Science and Technology Co., Ltd
- Jul 2027Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase 2 · Wuhan Createrna Science and Technology Co., Ltd
Studies
Open first, then newest update. How each study uses lanoracopan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruitingPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06134414Written as MY008211A tablets
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932744Written as MY008211A tablets
- Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932471Written as MY008211A tablets
- Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruitingPhase 2/3Wuhan Createrna Science and Technology Co., LtdNCT06933914Written as MY008211A tablets
- Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)Not yet recruitingPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06687174Written as MY008211A tablets
- To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy SubjectsNot yet recruitingPhase 1Wuhan Createrna Science and Technology Co., LtdNCT06543459Written as MY008211A tablets
- A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic FunctionCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT07625618Written as MY008211A tablets
- A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06050226Written as MY008211A tablets
- A Study of Multiple Ascending Doses MY008211A in Healthy AdultsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05828472Written as MY008211A tablets
- A Study of Single-dose MY008211A in Healthy AdultsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05642585Written as MY008211A tablets
- Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult SubjectsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05828485Written as MY008211A tablets
Codes
What other systems call lanoracopan · ClinicalTrials.gg INT018552
- UNII (FDA) Y5UN7AE8SFLANORACOPANOne source FDA
- NCI Thesaurus C215276LanoracopanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y5UN7AE8SF | LANORACOPAN | One source FDA |
| NCI Thesaurus | C215276 | Lanoracopan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.